Zymeworks
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Zymeworks and other ETFs, options, and stocks.About ZYME
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2).
CEOKenneth Harry Galbraith
CEOKenneth Harry Galbraith
Employees277
Employees277
HeadquartersMiddletown, Delaware
HeadquartersMiddletown, Delaware
Founded2003
Founded2003
Employees277
Employees277
ZYME Key Statistics
Market cap619.61M
Market cap619.61M
Price-Earnings ratio-5.10
Price-Earnings ratio-5.10
Dividend yield—
Dividend yield—
Average volume524.14K
Average volume524.14K
High today$8.93
High today$8.93
Low today$8.60
Low today$8.60
Open price$8.79
Open price$8.79
Volume400.59K
Volume400.59K
52 Week high$13.14
52 Week high$13.14
52 Week low$6.02
52 Week low$6.02
ZYME News
Seeking Alpha 5h
Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data - Seeking AlphaCaiaimage/Martin Barraud/iStock via Getty Images Zymeworks Inc. (NASDAQ:ZYME) is a clinical-stage biotechnology company focused on developing innovative therap...
Analyst ratings
57%
of 7 ratingsBuy
57.1%
Hold
42.9%
Sell
0%